Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-26T08:19:01.845Z Has data issue: false hasContentIssue false
  • English
  • Français

Realizing Informed Consent in Times of Controversy: Lessons from the SUPPORT Study

Published online by Cambridge University Press:  01 January 2021

Robert J. Morse  and
Robin Fretwell Wilson
Get access Rights & Permissions [Opens in a new window]

Abstract

This Essay examines the elegantly simple idea that consent to medical treatment or participation in human research must be “informed” to be valid. It does so by using as a case study the controversial clinical research trial known as the Surfactant, Positive Pressure, and Oxygenation Randomized Trial (“SUPPORT”). The Essay begins by charting, through case law and the adoption of the common rule, the evolution of duties to secure fully informed consent in both research and treatment. The Essay then utilizes the SUPPORT study, which sought to pinpoint the level of saturated oxygen that should be provided to extremely low birth weight infants to demonstrate modern complexities and shortcomings of the duty to secure informed consent. This Essay shows how the duty is measured by foreseeability of risks and benefits in human research and why federal regulators believed the tradeoffs in risk and benefits from differing oxygen levels administered in the support study were foreseeable. It then explores the contours of the duty to secure informed consent when applied to researchers who also serve as treating physicians, highlighting how common law duties differ in jurisdictions that apply the professional standard and those that apply the patient-centered material risk standard. This Essay provides new insight into what the law must do to make real the notion that [e]very human being of adult years and sound mind has a right to determine what shall be done with his body.”

Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 44 , Issue 3: Contemporary Challenges in Informed Consent: Law, Research Practice, and Ethics , Fall 2016 , pp. 402 - 418
Copyright
Copyright © American Society of Law, Medicine and Ethics 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

See, e.g., Banerjee, A. et al., “What Can Quality Improvement Learn From Evidence-Based Medicine?” Journal of the Royal Society of Medicine 105, no. 2 (2012): 55-59; S. D. Pearson, “Cost, Coverage, and Comparative Effectiveness Research: The Critical Issues for Oncology,” Journal of Clinical Oncology 30, no. 34 (2012): 4275-4281 (discussing the development of comparative effectiveness research in oncology as driven in part by a desire to constrain costs, which some found to be controversial); see generally R. Avraham, D. A. Hyman, and C. M. Silver, Economics of Health Law (forthcoming 2016). When unexamined, medical treatments that do more harm than good may go unchallenged for years. See A. Ghossain, “History of Mastectomy Before and After Halsted,” Lebanese Medical Journal 57, no. 2 (2009): 65–71.Google Scholar
See generally Young, P. L. and Olsen, L., The Healthcare Imperative: Lowering Costs and Improving Outcomes (Washington, D.C.: National Academies Press, 2010).Google Scholar
See, e.g., Wendler, D. et al., “The Standard of Care Debate: Can Research in Developing Countries Be Both Ethical and Responsive to Those Countries' Health Needs?” American Journal of Public Health 94, no. 6 (2004) 923-928 (discussing the ethics of international “standard of care” trials).Google Scholar
Id. These studies sometimes also have a control group, in addition to the two treatment arms. See id., at 924 (discussing the need for control groups in international “standard of care” trials). The value of the control group is that it “provid[es] rigorous evidence to guide what should be considered the standard of care.” Thompson, B. T. and Schoenfeld, D., “Usual Care as the Control Group in Clinical Trials of Nonpharmacologic Interventions,” Proceedings of the American Thoracic Society Journal 4, no. 7 (2007): 577-582, at 580; see also S. Tavernise, “Study of Babies Did Not Disclose Risks, U.S. Finds,” New York Times, April 10, 2013, available at <http://www.nytimes.com/2013/04/11/health/parents-of-preemies-werent-told-of-risks-in-study.html> (discussing the lack of a control group in SUPPORT) (last visited July 6, 2016).Google Scholar
Carlo, W. A. et. al., “Target Ranges of Oxygen Saturation in Extremely Preterm Infants,” New England Journal of Medicine 362, no. 21 (2010) 1959-1969, at 1960.Google Scholar
Id.Google Scholar
Id., at 1967.Google Scholar
Transcript, “Matters Related to Protection of Human Subjects and Research Considering Standard of Care Interventions,” August 28, 2013, available at http://www.hhs.gov/ohrp/sites/default/files/ohrp/newsroom/rfc/Public%20Meeting%20August%2028%2C%202013/supportmeetingtranscriptfinal.pdf [hereinafter Transcript] (testimony of Lois Shepherd); see also Editorial, “Subject to Question: Even When Conducting Clinical Trials to Study Widely Used Therapies, Researchers Must Ensure That They Disclose the Full Risks to Patients,” Nature 500 (2013): 377–377.Google Scholar
For a thoughtful treatment of the duties of medical personnel, especially medical researchers, see Menikoff, J. and Richards, E. P., What the Doctor Didn't Say: The Hidden Truth About Medical Research (New York: Oxford University Press, 2006).
Magnus, D. and Caplan, A. L., “Risk, Consent, and SUPPORT,” New England Journal of Medicine 368, no. 20 (2013): 1864-1865, at 1865; see also D. Magnus, “The SUPPORT Controversy and the Debate over Research within the Standard of Care,” American Journal of Bioethics 13, no. 12 (2013): 1-2 (introducing a special issue of the American Journal of Bioethics covering SUPPORT). For a recent controversy over a study authorized as “minimal risk” and waiving consent, see C. U. Niemann et al., “Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function,” New England Journal of Medicine 373, no. 5 (2015): 405-414; Letter from Public Citizen to Jerry Menikoff, Director, The Office for Human Research Protections, & to J. Thomas Puglisi, Chief Officer, The Office of Veterans' Affairs Office of Research Oversight, April 20, 2016, available at <http://www.citizen.org/documents/2315.pdf> (last visited July 6, 2016).Google Scholar
See Transcript, supra note 8.Google Scholar
Schloendorff v. Soc'y of N.Y. Hosp., 105 N.E. 92, 93 (N.Y. 1914).Google Scholar
See Berg, J. W. et al., Informed Consent: Legal Theory and Clinical Practice, 2nd ed. (New York: Oxford University Press, 2001): 2, 14; B. Lo, Resolving Ethical Dilemmas: A Guide For Clinicians, 2d ed. (New York: Wolters Kluwer, 2000): 3, 21.Google Scholar
See, generally, Presidential Commission for the Study of Bio-ethical Issues, “‘Ethically Impossible’: STD Research in Guatemala from 1946 to 1948,” (2011): at 99-101, available at <http://bioethics.gov/node/654> (last visited July 6, 2016). U.S. Dept. of Health and Human Services (DHHS), The Common Rule, available at <http://www.hhs.gov/ohrp/humansubjects/commonrule/> (last visited July 6, 2016).+(last+visited+July+6,+2016).+U.S.+Dept.+of+Health+and+Human+Services+(DHHS),+The+Common+Rule,+available+at++(last+visited+July+6,+2016).>Google Scholar
American Medical Association Ethics, “Opinion 8.08: Informed Consent,” 2006, available at <http://www.ama-assn.org/ama/pub/physician-resources/medical-ethics/code-medical-ethics/opinion808.page?> (last visited July 6, 2016).+(last+visited+July+6,+2016).>Google Scholar
Id.Google Scholar
See Wilson, , Promise of Informed Consent, supra note *, at 2 (citation omitted).Google Scholar
General Requirements for Informed Consent, 45 C.F.R. § 46.116 (2015).Google Scholar
Fifteen governmental departments have codified the Common Rule, requiring that the human research they fund adhere to it: Department of Agriculture, Department of Energy, National Aeronautics and Space Administration, Department of Commerce - National Institute of Standards and Technology, Consumer Product Safety Commission, Agency for International Development (USAID), Department of Housing and Urban Development, Department of Justice - National Institute of Justice, Department of Defense, Department of Education, Department of Veterans Affairs - Office of Research Oversight - Office of Research and Development, Environmental Protection Agency - Research and Development, Department of Health and Human Services, National Science Foundation, and the Department of Transportation. Three additional agencies follow the Common Rule via executive order: the Central Intelligence Agency, Department of Homeland Security, and Social Security Administration. U.S. Dep't of Health and Human Services, Federal Policy for the Protection of Human Subjects (‘Common Rule’), supra note 14.Google Scholar
See DHHS, supra note 14.Google Scholar
General Requirements for Informed Consent, 45 C.F.R. § 46.116.Google Scholar
See Transcript, supra note 8, at 24 (statement of Lois Shepard).Google Scholar
See Wilson, , “Promise of Informed Consent,” supra note *, at 4.Google Scholar
Id., at 3.Google Scholar
71 Nev. 280 (1955).Google Scholar
Id. at 282.Google Scholar
Id.Google Scholar
Id.Google Scholar
Id., at 283.Google Scholar
Id., at 281. Mrs. Corn also sued Dr. French for negligently removing her breast because he never performed the promised biopsy. Id.Google Scholar
Id.Google Scholar
Id., at 284.Google Scholar
Id. Mrs. Corn also failed to adduce sufficient evidence of Dr. French's negligence to reach the jury, the trial court found. Her own expert admitted that he also would have removed Mrs. Corn's her breast without a biopsy, even though “ordinarily[,]… a biopsy would have been done” first. Id., at 287.Google Scholar
Corn v. French, 74 Nev. 329, 330 (1958).Google Scholar
Corn, 71 Nev. at 285. Mrs. Corn's negligent diagnosis claim also should have gone to the jury. Id., at 290-91, 296.Google Scholar
Mrs. Corn asked for and received “[i]nstructions fixing defendant's liability if he operated without plaintiff's consent or after revocation of her consent.” The trial judge also instructed the jury that Dr. French would be liable if he did not follow “standard practice in the community;” in the end, the jury remained unconvinced. Id.Google Scholar
317 P.2d 170 (Cal. App. 1957).Google Scholar
Berg, , et al., supra note 13, at 44.Google Scholar
Salgo, 317 P.2d at 181.Google Scholar
Id. (citations omitted).Google Scholar
Id., at 172.Google Scholar
Id., at 177–78.Google Scholar
Id., at 180.Google Scholar
Id., at 172.Google Scholar
Id., at 181.Google Scholar
See Wilson, , Promise of Informed Consent, supra note *, at 6.Google Scholar
Id.Google Scholar
Culbertson v. Mernitz, 602 N.E.2d 98, 98–103 (Ind. 1992); id.Google Scholar
Canterbury v. Spence, 464 F.2d 772, 778 (D.C. Cir. 1972); see also Meisel, A., “Canterbury v. Spence: The Landmark Case,” in Johnson, S. H., Krause, J. H., Saver, R. S., and Fretwell Wilson, R., eds., Health Law & Bioethics: Cases in Context (Aspen Publishers, 2009): at 9, 17, 18, 19.Google Scholar
479 So. 2d 1150, 1152 (1985).Google Scholar
Id., at 1151.Google Scholar
Id.Google Scholar
Id., at 1152.Google Scholar
Id.Google Scholar
Id., at 1156.Google Scholar
519 P.2d 981 (Wash. 1974) (holding that custom was not determinative of the reasonableness inquiry in a medical negligence case).Google Scholar
Id., at 983.Google Scholar
Canterbury, 464 F.2d at 772.Google Scholar
Id., at 776.Google Scholar
Id., at 787 (citation omitted).Google Scholar
See Studdert, D. M. et al., “Geographic Variation in Informed Consent Law: Two Standards for Disclosure of Treatment Risks,” Journal of Empirical Legal Studies 4, no. 1 (2007): 103-124, at 105, 106.Google Scholar
Gatter, R., “Informed Consent Law and the Forgotten Duty of Physician Inquiry,” Loyola University Chicago Law Journal 31, no. 4 (2000): 557-597, at 559.Google Scholar
See e.g., Rowbotham, M. C. et al., “Interactive Informed Consent: Randomized Comparison with Paper Consents,” PLOS ONE 8, no. 3 (2013): 1 (finding that consent obtained using interactive devices, such as iPads and videos, is more effective than paper forms at conveying risks and benefits of procedures).Google Scholar
Id.; Hrobak, R. M. and Fretwell Wilson, R., “Emergency Contraceptives or ‘Abortion-Inducing’ Drugs? Empowering Women to Make Informed Decisions,” Washington & Lee Law Review 71, no. 2 (2014): 1386-1428, at 1426.Google Scholar
Gatter, R., “Walking the Talk of Trust in Human Subjects Research: The Challenge of Regulating Financial Conflicts of Interest,” Emory Law Journal 52, no. 1 (2003): 327-401, at 377.Google Scholar
Tenenbaum, E. M., “Revitalizing Informed Consent and Protecting Patient Autonomy: An Appeal to Abandon Objective Causation,” Oklahoma Law Review 64, no. 5 (2012): 697-758, at 720.Google Scholar
See Wilson, Promise of Informed Consent, supra note *, at 3.Google Scholar
See Ethically Impossible, supra note 14, at 99.Google Scholar
Id.Google Scholar
Id. (citations omitted).Google Scholar
Id.Google Scholar
Washington, H. A., Medical Apartheid: The Dark History Of Experimentation From Colonial Times To The Present (New York: Broadway Books, 2006).Google Scholar
Centers for Disease Control and Prevention, “The Tuskegee Timeline,” December 10, 2013, available at <http://www.cdc.gov/tuskegee/timeline.htm> (last visited July 6, 2016).+(last+visited+July+6,+2016).>Google Scholar
Id.Google Scholar
Gray, F. D., The Tuskegee Syphilis Study Montgomery: NewSouth Books 1998): 74-79; see also Wilson, Promise of Informed Consent supra note *, at 12.Google Scholar
This protection was enacted as part of the National Research Act of 1974 and codified with the Church Amendment. 42 U.S.C. § 300a-7(c) (2012); see also McLellan, D., “Ernest Hendon, 96; Tuskegee Syphilis Study's Last Survivor,” L.A. Times, January 25, 2004, available at <http://articles.latimes.com/2004/jan/25/local/me-hendon25> (last visited July 6, 2016).Google Scholar
General Requirements for Informed Consent, 45 C.F.R. § 46.116 (2015).Google Scholar
The trial was sponsored by the University of Pennsylvania and the Children's Hospital of Philadelphia. See Wilson, Estate of Gelsinger, supra note *, at 230.Google Scholar
Id., at 229.Google Scholar
Id., at 237-238, 242 (citing Letter from Dennis E. Baker, Assoc. Comm'r for Regulatory Affairs, FDA. Ctr. for Biologics Evaluation & Research to James M. Wilson, Inst. for Human Gene Therapy, Univ. of Pa. Health Sys. (Feb. 8, 2002), available at <http://www.fda.gov/RegulatoryInformation/FOI/ElectronicReadingRoom/ucm144564.htm> (notice of opportunity for hearing)). (notice of opportunity for hearing)).' href=https://scholar.google.com/scholar?q=Id.,+at+237-238,+242+(citing+Letter+from+Dennis+E.+Baker,+Assoc.+Comm'r+for+Regulatory+Affairs,+FDA.+Ctr.+for+Biologics+Evaluation+&+Research+to+James+M.+Wilson,+Inst.+for+Human+Gene+Therapy,+Univ.+of+Pa.+Health+Sys.+(Feb.+8,+2002),+available+at++(notice+of+opportunity+for+hearing)).>Google Scholar
Fretwell Wilson, R., “The Death of Jesse Gelsinger: New Evidence of the Influence of Money and Prestige in Human Research,” American Journal of Law & Medicine 36, nos. 2-3 (2010): 295-325, at 303-304 (reproducing the consent form at 7) [hereinafter Death of Gelsinger].Google Scholar
See id., at 299; Wilson, Estate of Gelsinger, supra note *, at 233.Google Scholar
Wilson, Estate of Gelsinger, supra note *, at 237 (reproducing the consent form for the study).Google Scholar
Wilson, Death of Gelsinger, supra note 81, at 303 (quoting the consent form for the study).Google Scholar
Id., at 304 (emphasis added).Google Scholar
See Appelbaum, P. S. et al., “False Hopes and Best Data: Consent to Research and the Therapeutic Misconception,” Hastings Center Report 17, no. 2 (1987): 20–25.CrossRefGoogle Scholar
Cho, M. K. and Magnus, D., “Therapeutic Misconception and Stem Cell Research,” Nature.com, September 27, 2007, available at <http://www.nature.com/stem-cells/2007/0709/070927/full/stemcells.2007.88.html> (citing P. Appelbaum, C. Lidz, and T. Grisso, “Therapeutic Misconception in Clinical Research: Frequency and Risk Factors,” IRB: Ethics of Human Research 26, no. 2 (2004): 1-8) (last visited July 6, 2016).Google Scholar
Wilson, Estate of Gelsinger, supra note *, at 251–253.Google Scholar
Wilson, Death of Gelsinger, supra note 81, at 305; see also id., at 237-238 (summarizing University of Pennsylvania documents valuing Wilson's equity interest in a sponsor of the research as between $28.5 and 33 million).Google Scholar
Wilson, Estate of Gelsinger, supra note *, at 248.Google Scholar
Id., at n.21Google Scholar
Berman v. Hutchinson Cancer Center, available at <http://biotech.law.lsu.edu/research/wa/Berman_v_Hutchinson.pdf> (last visited July 6, 2016).+(last+visited+July+6,+2016).>Google Scholar
Id., at 2.Google Scholar
Id., at 2–3.Google Scholar
Id., at 4.Google Scholar
Id.Google Scholar
Heath, D., “Hutch Settles Consent Case Out of Court,” Seattle Times, January 15, 2003, available at <http://community.seattletimes.nwsource.com/archive/?date=20030115&slug=hutch15> (last visited July 6, 2016).Google Scholar
Morreim, E. H., “Litigation in Clinical Research: Malpractice Doctrines Versus Research Realities,” Journal of Law, Medicine & Ethics 32, no. 3 (2004): 474-484, at 476 (citing Spenceley v. M.D. Anderson Cancer Center, 938 F. Supp. 398, 398 (S.D. Tex. 1996)).CrossRefGoogle Scholar
Oxygen saturation is a measurement of the level of oxygen in the blood. Target oxygen saturation rates for physicians treating adult patients is typically somewhere between 88 and 98 percent. Patients with low oxygen saturation levels are treated with “inspired oxygen” (FiO2)—that is, air with a higher concentration of oxygen then that found in the atmosphere. See, e.g., Driscoll, B. R. et. al., “BTS Guideline For Emergency Oxygen Use in Adult Patients,” British Thoracic Society, available at <https://www.brit-thoracic.org.uk/document-library/clinical-information/oxygen/emergency-oxygen-use-in-adult-patients-guideline/appendix-1-summary-of-recommendations-emergency-oxygen-use-in-adult-patients-guideline/> (last visited July 6, 2016). This essay shorthands oxygen saturation as oxygen throughout.+(last+visited+July+6,+2016).+This+essay+shorthands+oxygen+saturation+as+oxygen+throughout.>Google Scholar
See Carlo, supra note 5, at 1959.Google Scholar
CLD describes long-term respiratory problems that sometimes result from premature birth. See, e.g., Behrman, R. E. and Stith Butler, A., eds., Preterm Birth: Causes, Consequences, and Prevention (2007): 319–321.Google Scholar
Surfactant Positive Airway Pressure and Pulse Oximetry Trial in Extremely Low Birth Weight Infants (SUPPORT Study), University of Alabama at Birmingham Protocol 2 (emphasis added), Updated March 28, 2005, available at <https://www.nih.gov/sites/default/files/institutes/foia/support-protocol.pdf> [hereinafter UAB Protocol].+[hereinafter+UAB+Protocol].>Google Scholar
See Carlo, supra note 5, at 1960.Google Scholar
The Protocol outlined the trade-offs from oxygen therapy: [O]xygen toxicity can result in increased risk for CLD, retinopathy of prematurity (ROP), and other disorders. Alternatively, oxygen restriction may impair neurodevelopment.… While prevention of hyperoxia [excess oxygen] may decrease the risk for ROP and CLD, efforts to maintain lower oxygenation levels may result in an increase in periods of hypoxemia [low oxygen] because of the marked variability in oxygen in ELBW infants.… Thus, it is necessary to determine if lower oxygenation levels that may prevent ROP and CLD are deleterious for brain development and result in impaired neurologic outcome. UAB Protocol, supra note 102, at 2-3 (emphasis added).Google Scholar
Id.Google Scholar
Id,. at 2.Google Scholar
UAB Protocol, supra note 102, at 2 (“[T]here is no current agreement on the accepted SpO2 ranges for managing the ELBW infant from birth.”).Google Scholar
Cole, C. H. et. al., “Resolving Our Uncertainty about Oxygen Therapy,” Pediatrics 112, no. 6 (2003): 1415-1419, at 1417.Google Scholar
Id. (emphasis added). Similarly, a report published in 2011 based on references predating the February 2005 beginning of the SUPPORT Study, noted “two opposing concerns.” These were that “[l]ess inspired oxygen [under 90%] may increase patent ductus arteriosus, pulmonary vascular resistance and apnoea, and impair survival and neuro-development. More inspired oxygen [greater than 90%] may increase severe [retinopathy] and chronic lung disease.” Askie, L. M. et al., “Neoprom: Neonatal Oxygenation Prospective Meta-Analysis Collaboration Study Protocol,” BMC Pediatrics 11, no. 6 (2011): 1-9 at 3 (emphasis added).Google ScholarGoogle ScholarGoogle Scholar+(emphasis+added).+Although+one+study+reviewed+showed+“increased+rates+of+chronic+lung+disease+and+home+oxygen+use,”+the+review+concluded+that+“the+question+of+what+is+the+optimal+target+range+for+maintaining+blood+oxygen+levels+in+preterm/LBW+infants+was+not+answered+by+the+data+available+for+inclusion+in+this+review.”+Id.+(emphasis+added).>Google Scholar
See UAB Protocol, supra note 102, at 2.Google Scholar
Id., at 17.Google Scholar
Macklin, R. and Shepherd, L., “Informed Consent and Standard of Care: What Must Be Disclosed,” American Journal of Bio-ethics 13, no. 12 (2013): 9-13, at 11.Google Scholar
Id. (“According to the available evidence, however, the likelihood that infants outside the study would have been intentionally maintained at the lower oxygen target range was very low.”) (citing C. G. Anderson, W. E. Benitz, and A. Madan, “Retinopathy of Prematurity and Pulse Oximetry: A National Survey of Recent Practices,” Journal of Perinatology 24, no. 3 (2004): 164-168, at 164-168) (surveying 120 NICUs).Google Scholar
Lantos, J. D. and Feudtner, C., “SUPPORT and the Ethics of Study Implementation: Lessons for Comparative Effectiveness Research from the Trial of Oxygen Therapy for Premature Babies,” Hastings Center Report 45, no. 1 (2015): 30-40, at 37 (“Many neonatologists chose other [oxygen saturation] targets as their standard NICU protocols. Rather than imagining that the conventional treatment at the time was to target 85 to 95 percent, a more accurate statement would be that, in each NICU, there was a different target and that most of those targets were within the range of 85 to 95 percent. Some, as part of their standard practice, targeted the lower end of the range. Others targeted the higher end.”).Google Scholar
UAB Protocol, supra note 102, at 17.Google Scholar
Id. (“These interventions will be delivered using specially developed pulse oximeters whose displays (the actual readings seen by caretakers) will be adjusted so that the randomized range of SpO2 (either 85%–89%, or 91%–95%) will be indicated by a range of 88%–92%.”).Google Scholar
Id.Google Scholar
Id., at 17–18.Google Scholar
Letter from the Office for Human Research Protections to the University of Alabama at Birmingham at 3, June 4, 2013, available at <http://www.hhs.gov/ohrp/detrm_letrs/YR13/jun13a.pdf> [hereinafter June 4, 2013 Letter] (last visited July 6, 2016).+[hereinafter+June+4,+2013+Letter]+(last+visited+July+6,+2016).>Google Scholar
See Carlo, supra note 5, at 1960.Google Scholar
BPD is a “form of chronic lung disease that affects newborns (mostly premature) and infants. It results from damage to the lungs caused by mechanical ventilation (respirator) and long-term use of oxygen.” Bronchopulmonary Dysplasia, American Lung Association http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/bronchopulmonary-dysplasia/ (Last visited May 5, 2016).Google Scholar
See UAB Protocol, supra note 102, at 19.Google Scholar
See Carlo, supra note 5, at 1960 (noting ROP also causes “other visual disabilities in preterm infants. The incidence of [ROP] was increased with exposure to unrestricted oxygen supplementation in preterm infants in randomized controlled trials performed in the 1950s”). Id.Google Scholar
Id.Google Scholar
See Letter from the Office of Human Research Protections to the University of Alabama at Birmingham at 5, March 7, 2013, available at <http://www.hhs.gov/ohrp/detrm_letrs/YR13/mar13a.pdf> [hereinafter March 7, 2013 Letter] (last visited July 6, 2016).+[hereinafter+March+7,+2013+Letter]+(last+visited+July+6,+2016).>Google Scholar
See Editorial, “An Ethical Breakdown,” New York Times, Apr 15, 2013, available at <http://www.nytimes.com/2013/04/16/opinion/an-ethical-breakdown-in-medical-research.html?_r=0> (last visited July 6, 2016).+(last+visited+July+6,+2016).>Google Scholar
Surfactant Positive Airway Pressure and Pulse Oximetry Trial in Extremely Low Birth Weight Infants (SUPPORT Study), University of Alabama at Birmingham Consent Form 2 (Oct. 1, 2004) (emphasis added) available at <http://www.citizen.org/documents/support-study-consent-form.pdf> [hereinafter UAB Consent Form] (last visited July 6, 2016).+[hereinafter+UAB+Consent+Form]+(last+visited+July+6,+2016).>Google Scholar
Id., at 2 (emphasis added).Google Scholar
See Macklin and Shepherd, supra note 112, at 11.Google Scholar
UAB Consent Form, supra note 128, at 4.Google Scholar
Id. (emphasis added).Google Scholar
Id.Google Scholar
See UAB Protocol, supra note 102, at 17–18.Google Scholar
Memorandum from Suzanne Murrin, Deputy Inspector General for Evaluations and Inspections, to Jerry Menikoff, Director, OHRP (Sept. 14, 2014), available at <http://oig.hhs.gov/oei/reports/oei-01-14-00560.pdf> (last visited July 6, 2016).+(last+visited+July+6,+2016).>Google Scholar
March 7, 2013 Letter, supra note 126, at 2, 9. Amended to remove an institution not involved in SUPPORT and resent on March 7, 2013. Id.Google Scholar
Id., at 10.Google Scholar
Id., at 4 (citing UAB Protocol at 2, 3).Google Scholar
June 4, 2013 Letter, supra note 119, at 2.Google Scholar
Id., at 9.Google Scholar
See March 7, 2013 Letter, supra note 126, at 12. While it is true that these other trials were shut down based in part on SUPPORT findings, depending on how early the trade-off between blindness and death emerged during the SUPPORT study, SUPPORT researchers may have had a duty to—as two international counterparts had done—“shut down [the study] early.” N. Feldman, “Courts Can't Mend a Parent's Broken Heart,” Bloomberg View, September 10, 2015, available at <http://www.bloombergview.com/articles/2015-09-10/courts-can-t-mend-a-parent-s-broken-heart> (making this observation about the international studies).+(making+this+observation+about+the+international+studies).>Google Scholar+(last+visited+July+6,+2016);+see+also+Sica,+D.+A.,+“Premature+Termination+of+Clinical+Trials+-+Lessons+Learned,”+4(3)+Journal+of+Clinical+Hypertension+(2002):+219-225,+at+220+(discussing+the+“[s]everal+factors+[that]+can+influence+the+decision+to+terminate+an+ongoing+clinical+trial+including+ethical+concerns,+alterations+in+accepted+clinical+practice+that+make+the+continuation+of+a+clinical+trial+unwise,+and/or+reaching+a+positive+or+negative+statistical+end+point+earlier+than+anticipated”)+(emphasis+added);+see+Niemann,+supra+note+10+(detailing+a+study+that+was+terminated+after+a+negative+endpoint+became+evident).>Google Scholar
See, e.g., Drazen, J. M. et al., “Informed Consent and SUPPORT,” New England Journal of Medicine 368, no. 20 (2013): 1929-1931, at 1930; Carlo, supra note 5; see also K. Hudson, A. Guttmacher, and Francis Collins, “In Support of SUPPORT: A View from the NIH,” New England Journal of Medicine 368, (2013): 2349–2351.Google Scholar
Drazen, supra note 142, at 1930.Google Scholar
Wilfond, B. S. et al., “The OHRP and SUPPORT,” New England Journal of Medicine 368 (2013), available at <http://www.nejm.org/doi/full/10.1056/NEJMc1307008> (last visited July 6, 2016).Google Scholar
See, e.g., Lantos and Feudtner, supra note 114, at 37.Google Scholar
See UAB Protocol, supra note 102, at 3.Google Scholar
See Drazen, supra note 142, at 1930.Google Scholar
Carlo, W. A., et al., “Oxygen-Saturation Targets in Extremely Preterm Infants,” New England Journal of Medicine 368, (2013): 1949-1950, at 1949-1950, available at <http://www.nejm.org/doi/full/10.1056/NEJMc1304827> (last visited July 6, 2016).Google Scholar
See e.g., Macklin, R. et al., “The OHRP and SUPPORT—Another View,” New England Journal of Medicine 369, no. 3 (2013) available at <http://www.nejm.org/doi/full/10.1056/NEJMc1308015> (last visited July 6, 2016).Google Scholar
Id. (emphasis added).Google Scholar
See June 4, 2013, Letter, supra note 119, at 5.Google Scholar
Id.Google Scholar
Id., at 2.Google Scholar
Id.Google Scholar
Id., at 4.Google Scholar
See June 4, 2013 Letter, supra note 119, at 5 n.8 (citing the BOOST Study Consent Form (emphasis modified)).Google Scholar
Id.Google Scholar
Id. (citing Surfactant Positive Airway Pressure and Pulse Oximetry Trial in Extremely Low Birth Weight Infants (SUPPORT Study) Tufts University Consent Form (Oct. 1, 2004) available at <http://www.citizen.org/documents/support-study-consent-form.pdf> (noting that “at that center, for clinical purposes, oxygen saturation was ‘kept between 88 and 94%,’” rather than the minimum 85% and maximum 95% used at UAB) (last visited July 6, 2016).+(noting+that+“at+that+center,+for+clinical+purposes,+oxygen+saturation+was+‘kept+between+88+and+94%,’”+rather+than+the+minimum+85%+and+maximum+95%+used+at+UAB)+(last+visited+July+6,+2016).>Google Scholar
Id.Google Scholar
See Raab, L., “Sen. Howard Baker Asked: What Did Nixon Know and When Did He Know It?” Los Angeles Times, June 26, 2014, available at <http://www.latimes.com/nation/politics/politicsnow/la-na-pn-howard-baker-watergate-20140626-htmlstory.html> (last visited July 6, 2016).Google Scholar
Black's Law Dictionary defines “Foreseeability” as “[t]he quality of being reasonably anticipatable.” See Black's Law Dictionary 10th ed., s.v., “Foreseeability,” (2014).Google Scholar
See June 4, 2013 Letter, supra note 119, at 2 (emphasis added).Google Scholar
See id., at 2 n.2, 5 n.8 (collecting studies that recognized these risks); Part II.A, supra.Google Scholar
Id.Google Scholar
See Transcript, supra note 8.Google Scholar
Although the notice and comment period has closed, final guidance has yet to be issued. OHRP, HHS, “Draft Guidance on Disclosing Reasonably Foreseeable Risks in Research Evaluating Standards of Care,” Federal Register 79, (Oct. 24, 2014): 63629-63634, at 63632.Google Scholar
Id. (emphasis added).Google Scholar
See June 4, 2013 Letter, supra note 119, at 4.Google Scholar
79(206) Federal Register 63629, 63632.Google Scholar
Fifth Amended Complaint at ¶ 50, Looney v. Moore, 2015 WL 4773747 (N.D. AL. 2015) (No. 2:13-cv-00733-UNAS-KOB).Google Scholar
Id., at ¶ 54.Google Scholar
See, e.g., Dr. Carlo's Motion for Summary Judgment at 1–8, Looney v. Moore, 2015 WL 4773747 (N.D. AL. 2015) (No. 2:13-cv-00733-UNAS-KOB).Google Scholar
Looney v. Moore, 2015 WL 4773747 at *8 (N.D. AL. 2015).Google Scholar
Looney v. Moore, 2015 WL 4773747 at *8 (N.D. AL. 2015) appealed sub. nom. Lewis v. Moore (11th Cir. 2015).Google Scholar
See Part I.A. supra. See Menikoff and Richards, supra note 9 for an explanation of the treating physician's disclosure duty. See also Annas, G. J. and Annas, C. L., “Legally Blind: The Therapeutic Illusion in the SUPPORT Study of Extremely Premature Infants,” Journal of Contemporary Health Law & Policy 30, no. 1 (2014): 1-36, at 25-26 (briefly discussing the intersection between research and treatment disclosure duties).Google Scholar
See UAB Protocol, supra note 102, at 17.Google Scholar
Id., at 19 (forbidding the use of steroids within the first 21 days of an infant's life).Google Scholar
Id., at 17.Google Scholar
Transcript, supra note 8, at 120 (quoting parents of Dagen Pratt, an infant enrolled in SUPPORT, as testifying that “[w] e want to know as information comes in, why the risks and intent of the study were not clear. If it were clear, we wouldn't have taken part in the study.”).Google Scholar
See UAB Protocol, supra note 102, at 17–18.Google Scholar
See, e.g., Lantos and Feudtner, supra note 114, at 37.Google Scholar
The T.J. Hooper, 60 F.2d 737, 740 (2d Cir. 1932); see, e.g., Helling v. Carey, 519 P.2d 981 (1974) (holding that custom was not determinative of the reasonableness inquiry in a medical negligence inquiry, and citing The T.J. Hooper).Google Scholar
Looney v. Moore, 2015 WL 4773747 at *8 (N.D. AL. 2015).Google Scholar
Schloendorff v. Soc'y of N.Y. Hosp., 105 N.E. 92, 93 (N.Y. 1914).Google Scholar
See, e.g., Transcript, supra note 8.Google Scholar
Id., at 120–21 (quoting a parent of Dagen Pratt).Google Scholar